https://www.nasdaq.com/press-release/avrobio-reprioritizes-pipeline-programs-2022-01-04
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-12-07
https://www.nasdaq.com/press-release/avrobio-presents-clinician-experience-with-fab-gt-clinical-trial-and-updated-safety
https://www.nasdaq.com/press-release/avrobio-to-present-at-two-upcoming-investor-conferences-in-november-2021-11-09
https://www.nasdaq.com/press-release/avrobio-to-present-clinical-and-preclinical-data-at-the-14th-iciem-conference-2021-11
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2021-11-05
https://www.nasdaq.com/press-release/avrobio-reports-third-quarter-2021-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/avrobio-receives-rare-pediatric-disease-designation-from-the-u.s.-fda-for-avr-rd-05-a
https://www.nasdaq.com/press-release/avrobio-announces-the-appointment-of-essra-ridha-m.d.-mrcp-ffpm-as-chief-medical
https://www.nasdaq.com/press-release/avrobio-to-present-at-the-jefferies-virtual-gene-therapy-editing-summit-2021-10-20
https://www.nasdaq.com/press-release/avrobio-reports-new-interim-safety-data-across-investigational-gene-therapies-for
https://www.nasdaq.com/press-release/avrobio-to-present-new-clinical-and-preclinical-data-across-multiple-programs-at-the
https://www.nasdaq.com/press-release/avrobio-to-present-new-clinical-and-preclinical-data-across-multiple-programs-at-the
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-10-05
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-09-03
https://www.nasdaq.com/press-release/avrobio-to-participate-at-four-upcoming-investor-conferences-2021-09-01
https://www.nasdaq.com/press-release/avrobio-reports-second-quarter-2021-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-08-04
https://www.nasdaq.com/press-release/avrobio-to-present-at-two-upcoming-investor-conferences-in-august-2021-08-02
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-07-08
https://www.nasdaq.com/press-release/avrobio-to-present-at-the-jmp-securities-life-sciences-conference-2021-06-10
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2021-06-04
https://www.nasdaq.com/press-release/avrobio-reports-first-quarter-2021-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-05-06
https://www.nasdaq.com/press-release/avrobio-provides-regulatory-update-on-investigational-avr-rd-01-for-fabry-disease
https://www.nasdaq.com/press-release/avrobio-to-present-clinical-and-preclinical-data-at-the-asgct-24th-annual-meeting
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-04-06
https://www.nasdaq.com/press-release/avrobio-reports-fourth-quarter-and-fiscal-year-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-03-05
https://www.nasdaq.com/press-release/avrobio-receives-orphan-drug-designation-from-the-european-commission-for-avr-rd-04
https://www.nasdaq.com/press-release/avrobio-to-present-at-three-upcoming-investor-conferences-in-march-2021-02-25
https://www.nasdaq.com/press-release/avrobio-announces-100-kidney-substrate-reduction-at-12-months-post-gene-therapy-in
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-02-05
https://www.nasdaq.com/press-release/avrobio-announces-multiple-clinical-data-presentations-posters-and-events-at-17th
https://www.nasdaq.com/press-release/avrobio-to-present-at-the-cowen-2021-gene-therapy%3a-cmc-regulatory-summit-2021-01-22
https://www.nasdaq.com/press-release/avrobio-announces-the-appointment-of-diana-m.-escolar-m.d.-as-chief-medical-officer
https://www.nasdaq.com/press-release/avrobio-to-present-at-the-icr-conference-2021-2021-01-08
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2021-01-07
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2020-12-04
https://www.nasdaq.com/press-release/avrobio-announces-closing-of-underwritten-public-offering-2020-11-24
https://www.nasdaq.com/press-release/avrobio-announces-pricing-of-underwritten-public-offering-of-%2475-million-of-common
https://www.nasdaq.com/press-release/avrobio-announces-proposed-public-offering-of-common-stock-2020-11-19
https://www.nasdaq.com/press-release/avrobio-announces-new-positive-clinical-data-and-preclinical-data-as-well-as-expanded
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-11-06
https://www.nasdaq.com/press-release/avrobio-reports-third-quarter-2020-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/avrobio-receives-orphan-drug-designation-from-the-european-commission-for-avr-rd-01
https://www.nasdaq.com/press-release/avrobio-to-share-clinical-and-pipeline-updates-at-virtual-rd-day-2020-10-26
https://www.nasdaq.com/press-release/avrobio-appoints-dr.-gail-farfel-to-its-board-of-directors-2020-10-21
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-10-06
https://www.nasdaq.com/press-release/avrobio-expands-lentiviral-gene-therapy-pipeline-with-program-for-hunter-syndrome
https://www.nasdaq.com/press-release/avrobio-receives-orphan-drug-designation-from-the-european-medicines-agency-for-avr
https://www.nasdaq.com/press-release/avrobio-to-present-at-two-upcoming-investor-conferences-2020-09-25
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2020-09-04
https://www.nasdaq.com/press-release/avrobio-to-present-at-three-upcoming-investor-conferences-2020-09-03
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-08-07
https://www.nasdaq.com/press-release/avrobio-reports-second-quarter-2020-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/avrobio-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conference-2020-08
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-07-08
https://www.nasdaq.com/press-release/avrobio-announces-new-patients-dosed-in-gaucher-disease-and-cystinosis-clinical
https://www.nasdaq.com/press-release/avrobio-announces-the-appointment-of-kim-raineri-as-chief-manufacturing-and
https://www.nasdaq.com/press-release/avrobio-presents-new-preclinical-data-on-lentiviral-gene-therapy-program-for-pompe
https://www.nasdaq.com/press-release/avrobio-reports-updated-clinical-data-from-investigational-gene-therapy-programs-for
https://www.nasdaq.com/press-release/avrobio-reports-1q-2020-financial-results-and-provides-business-update-2020-05-07
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-05-06
https://www.nasdaq.com/press-release/avrobio-and-magenta-therapeutics-announce-collaboration-to-evaluate-targeted-antibody
https://www.nasdaq.com/press-release/avrobio-to-present-new-clinical-and-preclinical-data-at-upcoming-american-society-of
https://www.nasdaq.com/press-release/avrobio-to-collaborate-with-saladax-biomedical-on-new-high-speed-diagnostic-assay
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-04-03
https://www.nasdaq.com/press-release/avrobio-outlines-response-to-covid-19-and-current-assessment-of-business-impact-2020
https://www.nasdaq.com/press-release/avrobio-to-participate-in-upcoming-april-investor-conferences-2020-03-26
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2020-03-25
https://www.nasdaq.com/press-release/avrobio-reports-fourth-quarter-and-fiscal-year-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/avrobio-receives-orphan-drug-designation-from-u.s.-fda-for-avr-rd-04-for-cystinosis
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-03-05
https://www.nasdaq.com/press-release/avrobio-to-present-at-the-cowen-and-company-40th-annual-health-care-conference-2020
https://www.nasdaq.com/press-release/avrobio-announces-closing-of-underwritten-public-offering-2020-02-18
https://www.nasdaq.com/press-release/avrobio-announces-pricing-of-underwritten-public-offering-of-%24100-million-of-common
https://www.nasdaq.com/press-release/avrobio-announces-proposed-public-offering-of-common-stock-2020-02-12
https://www.nasdaq.com/press-release/avrobio-presents-positive-initial-data-for-its-investigational-cystinosis-program-and
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2020-02-06
https://www.nasdaq.com/press-release/avrobio-announces-clinical-data-presentation-and-multiple-events-at-worldsymposiumtm
https://www.nasdaq.com/press-release/avrobio-announces-clinical-and-regulatory-progress-for-gaucher-disease-program-2020
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2020-01-09
https://www.nasdaq.com/press-release/avrobio-announces-first-patient-dosed-using-platotm-platform-2019-12-19
https://www.nasdaq.com/press-release/avrobio-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2019-12-16
https://www.nasdaq.com/press-release/avrobio-inc.-reports-third-quarter-2019-financial-results-and-provides-business
https://www.nasdaq.com/press-release/avrobio-receives-orphan-drug-designation-from-the-u.s.-fda-for-avr-rd-02-for-the
https://www.nasdaq.com/press-release/avrobio-appoints-holly-may-as-chief-commercial-officer-2019-10-22
